Seeking Alpha

Kythera Biopharmaceutical will sell 4.4M shares in its Nasdaq IPO at $16 each, the top end of...

Kythera Biopharmaceutical will sell 4.4M shares in its Nasdaq IPO at $16 each, the top end of the estimated range. The biotech's lead candidate is ATX-101, a drug for reducing submental fat, or "double chins." Kythera will used the proceeds from its offering to help fund the ongoing Phase III trials of ATX-101. The company will trade under the KYTH ticker symbol.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|